New ATC 5th levels
List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.
Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.
ATC code | ATC level name | Deadline for objection to temporary codes | Implementation in ATC/DDD index |
---|---|---|---|
V10XA04 | iodine (131I) apamistamab | 01.02.2024 | 2025 |
V09IX18 | flotufolastat (18F) | 01.02.2024 | 2025 |
V04CX12 | xenon | 01.02.2024 | 2025 |
S01XA32 | avacincaptad pegol | 01.02.2024 | 2025 |
S01EE52 | latanoprost and dorzolamide | 01.02.2024 | 2025 |
S01EA55 | brimonidine and ripasudil | 01.02.2024 | 2025 |
S01AX25 | lotilaner | 01.02.2024 | 2025 |
P01AB53 | tinidazole and diloxanide | 01.02.2024 | 2025 |
P01AB08 | satranidazole | 01.02.2024 | 2025 |
N07XX24 | trofinetide | 01.02.2024 | 2025 |
N07BB06 | ondelopran | 01.02.2024 | 2025 |
N06AX31 | zuranolone | 01.02.2024 | 2025 |
N02CD08 | zavegepant | 01.02.2024 | 2025 |
M01AE19 | loxoprofen | 01.02.2024 | 2025 |
L04AA60 | remibrutinib | 01.02.2024 | 2025 |
L04AJ10 | vilobelimab | 01.02.2024 | 2025 |
L04AG17 | seniprutug | 01.02.2024 | 2025 |
L04AC26 | goflikicept | 01.02.2024 | 2025 |
L01XX81 | nirogacestat | 01.02.2024 | 2025 |
L01XM04 | vorasidenib | 01.02.2024 | 2025 |
L01XM03 | olutasidenib | 01.02.2024 | 2025 |
L01XH07 | resminostat | 01.02.2024 | 2025 |
L01XH06 | tucidinostat | 01.02.2024 | 2025 |
L01FX34 | odronextamab | 01.02.2024 | 2025 |
L01FX33 | tarlatamab | 01.02.2024 | 2025 |
L01FX32 | elranatamab | 01.02.2024 | 2025 |
L01FX31 | zolbetuximab | 01.02.2024 | 2025 |
L01FD07 | zanidatamab | 01.02.2024 | 2025 |
L01EX28 | repotrectinib | 01.02.2024 | 2025 |
L01EL06 | tirabrutinib | 01.02.2024 | 2025 |
L01DC05 | utidelone | 01.02.2024 | 2025 |
J07BB05 | influenza, RNA-based vaccine | 01.02.2024 | 2025 |
J07AH11 | meningococcus A,B,C,Y,W-135, pentavalent purified polysaccharides antigen conjugated and factor H binding protein | 01.02.2024 | 2025 |
J06BD09 | sipavibart | 01.02.2024 | 2025 |
J05AX32 | riamilovir | 01.02.2024 | 2025 |
J05AR29 | emtricitabine, tenofovir alafenamide and dolutegravir | 01.02.2024 | 2025 |
J05AP14 | narlaprevir | 01.02.2024 | 2025 |
J05AG07 | elsulfavirine | 01.02.2024 | 2025 |
J04AM12 | rifampicin, pyrazinamide, isoniazid and levofloxacin | 01.02.2024 | 2025 |
J04AM11 | rifabutin, pyrazinamide and protionamide | 01.02.2024 | 2025 |
J04AM10 | pyrazinamide, ethambutol, protionamide and lomefloxacin | 01.02.2024 | 2025 |
J04AM09 | pyrazinamide, ethambutol, isoniazid and lomefloxacin | 01.02.2024 | 2025 |
J04AC02 | ftivazide | 01.02.2024 | 2025 |
J01XX13 | gepotidacin | 01.02.2024 | 2025 |
J01RA19 | tetracycline and nystatin | 01.02.2024 | 2025 |
J01RA18 | ofloxacin and tinidazole | 01.02.2024 | 2025 |
J01RA17 | ofloxacin and nitazoxanide | 01.02.2024 | 2025 |
J01DF51 | aztreonam and beta-lactamase inhibitor | 01.02.2024 | 2025 |
C10BX22 | rosuvastatin and nebivolol | 01.02.2024 | 2025 |
C10BA13 | pitavastatin and ezetimibe | 01.02.2024 | 2025 |
C09XX01 | sparsentan | 01.02.2024 | 2025 |
C08DA03 | etripamil | 01.02.2024 | 2025 |
C02KX06 | sotatercept | 01.02.2024 | 2025 |
C01EB25 | acoramidis | 01.02.2024 | 2025 |
B06AC07 | garadacimab | 01.02.2024 | 2025 |
B03XA10 | efepoetin alfa | 01.02.2024 | 2025 |
B03XA09 | molidustat | 01.02.2024 | 2025 |
B02BD17 | fidanacogene elaparvovec | 01.02.2024 | 2025 |
A16AX24 | govorestat | 01.02.2024 | 2025 |
A10XX02 | donislecel | 01.02.2024 | 2025 |
A10BK09 | enavogliflozin | 01.02.2024 | 2025 |
A10BD30 | gemigliptin and dapagliflozin | 01.02.2024 | 2025 |
A02BC11 | Ilaprazole | 01.02.2024 | 2025 |
A02BC10 | fexuprazan | 01.02.2024 | 2025 |
Last updated: 2023-12-12